Sarepta Therapeutics (NASDAQ:SRPT) Given New $182.00 Price Target at Piper Sandler

Sarepta Therapeutics (NASDAQ:SRPT) had its target price trimmed by Piper Sandler from $200.00 to $182.00 in a research report released on Wednesday,Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock.

A number of other brokerages have also recently issued reports on SRPT. Evercore ISI decreased their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Guggenheim upped their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. UBS Group raised their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Finally, Needham & Company LLC lowered their price target on Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating on the stock in a research report on Wednesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $175.77.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $137.94 on Wednesday. The stock has a market capitalization of $13.18 billion, a P/E ratio of 110.35 and a beta of 0.81. The business has a 50-day moving average of $121.90 and a two-hundred day moving average of $131.39. Sarepta Therapeutics has a fifty-two week low of $78.67 and a fifty-two week high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Insider Activity at Sarepta Therapeutics

In related news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. This represents a 14.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 7.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Tidal Investments LLC boosted its holdings in shares of Sarepta Therapeutics by 8.5% during the 1st quarter. Tidal Investments LLC now owns 2,902 shares of the biotechnology company’s stock worth $376,000 after buying an additional 228 shares during the period. Comerica Bank boosted its holdings in shares of Sarepta Therapeutics by 489.4% in the 1st quarter. Comerica Bank now owns 3,336 shares of the biotechnology company’s stock valued at $432,000 after purchasing an additional 2,770 shares in the last quarter. New Covenant Trust Company N.A. acquired a new position in Sarepta Therapeutics during the 1st quarter worth about $32,000. Farallon Capital Management LLC raised its position in shares of Sarepta Therapeutics by 102.8% in the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after acquiring an additional 1,243,427 shares in the last quarter. Finally, Cetera Investment Advisers increased its position in Sarepta Therapeutics by 27.6% in the 1st quarter. Cetera Investment Advisers now owns 11,991 shares of the biotechnology company’s stock valued at $1,552,000 after buying an additional 2,590 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.